AIM ImmunoTech CEO to Participate in Two Upcoming Investor
OCALA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas Equels, Chief Executive Officer of...
Stay updated with breaking news from Thomas Equels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OCALA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas Equels, Chief Executive Officer of...
/PRNewswire/ -- BioFlorida has announced five new board members who will support the organization's effort to grow the life sciences industry in Florida. "The...
AIM hopes to commence inhalation safety testing before year-end AIM entered into the material transfer and research agreement to study the utilization of an innovative Smoore inhalation delivery device AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) has entered into a two-year agreement extension with Shenzhen Smoore Technology Limited (Smoore) with the goal of developing Ampligen as a potential inhalation therapy for coronavirus (COVID-19) and other respiratory viral diseases. In April 2020, AIM entered into the material transfer and research agreement to study the utilizatio...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive Mydecine Innovations Group Inc (NEO:MYCO) (OTCMKTS:MYCOF) (FRA:0NFA) announced that it ended the first quarter of 2021 with cash and equivalents of C$11.3 million, which the company said will help it advance its intellectual property portfolio, build out its clinical trial calendar, expand its European operations and develop its technology division. As well, Mydecine said its strategic partnerships are expected to expand its drug development...
8 April 2021 (Last Updated April 8th, 2021 08:00) AIM ImmunoTech has reported that no serious adverse events were observed in Cohort 1 of a Phase I AMP-COV-100 (CHDR2049) clinical study of its drug Ampligen as an intranasal therapy for Covid-19. With this latest development, the company will soon initiate dose escalation in Cohort 2 of the trial. Credit: Gerd Altmann from Pixabay. Share Article AIM ImmunoTech has reported that no serious adverse events were observed in Cohort 1 of a Phase I AMP-COV-100 (CHDR2049) clinical study of its drug Amplig...